Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Dercher Enterprises, Inc., DBA Gordon Laboratories
WARNING LETTER
•Dercher Enterprises, Inc., DBA Gordon Laboratories•March 29, 2019

Dercher Enterprises, Inc., DBA Gordon Laboratories – FDA Warning Letter, Mar 29, 2019

Record Details

The FDA issued a Warning Letter to Gordon Laboratories following a March 2019 inspection, citing significant CGMP violations for finished pharmaceuticals (21 CFR parts 210 and 211). The firm's drug products, including Monsel's Solution, were deemed adulterated. CGMP deficiencies included a failure to thoroughly investigate unexplained discrepancies and recurring super-potency issues with Monsel’s Solution (21 CFR 211.192). The firm also failed to conduct appropriate microbiological testing, resulting in contamination of Monsel’s Solution (21 CFR 211.165(b)). Furthermore, Gordon Laboratories lacked an adequate quality control unit and failed to establish and follow adequate written procedures (21 CFR 211.22(a) & 21 CFR 211.22(d)), impacting CAPA, material storage, and vendor qualification. Beyond CGMP, the letter cited "TRI-CHLOR," "SILVER NITRATE SOLUTION 10%," "SILVER NITRATE SOLUTION 25%," and "SILVER NITRATE SOLUTION 50%" as unapproved new drugs, marketed without FDA approval (sections 505(a) and 301(d) of the FD&C Act). Additionally, "TRI-CHLOR," "SILVER NITRATE SOLUTION 25%," and "SILVER NITRATE SOLUTION 50%" were misbranded, lacking adequate directions for use for laymen as they are prescription drugs (section 502(f)(1) of the FD&C Act). The FDA requires prompt corrective actions, a detailed response within 15 working days, and strongly recommends a CGMP consultant. Non-compliance could lead to legal action, including product seizure, injunctions, and denial of applications or export certificates.

Company
Dercher Enterprises, Inc., DBA Gordon Laboratories
Inspection date
March 29, 2019
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations I
Person
  • Diana Amador-Toro (District Director)
View Company Profile

ID · 9710fe6a-0c06-4a42-8a6f-1cb30e824780

Violation Codes10
21 U.S.C. 353(b)(1)21 U.S.C. 351(a)(2)(B)21 U.S.C. 331(a)21 CFR 21021 CFR 21121 CFR 211.19221 CFR 211.165(b)21 CFR 211.22(a)21 CFR 211.22(d)21.U.S.C. 355(a)

Full citation text and observation details available on the Dashboard.

Other documents for Dercher Enterprises, Inc., DBA Gordon Laboratories
  • 483 - 2023-09-20September 20, 2023
  • 483 - 2022-06-13June 13, 2022
  • 483 - 2021-05-04May 4, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Dercher Enterprises, Inc., DBA Gordon Laboratories
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.